Sequential Skin launches test to assess ingredient effect on microbiome

By Will Chu

- Last updated on GMT

Dr Albert Dashi, CSO/cofounder and Petronille Houdart, PharmD and skincare director in the Sequential lab. ©Sequential Skin
Dr Albert Dashi, CSO/cofounder and Petronille Houdart, PharmD and skincare director in the Sequential lab. ©Sequential Skin

Related tags: sequential skin, sequential bio, microbiome

Sequential Skin has released details of an in-vivo microbiome testing solution that allows firms greater insights into the effects their ingredients have on the body's microbiome.

Launched earlier this month, Sequential Bio comprises of a series of assays that provide microbiome quantification allowing for higher resolution of key species and strain-level.

Sequencing of the micro-organisms found on the body, before and after product usage, is then used to delve further into the microbial diversity particularly the micro-organisms known to play a role in a healthy microbiome.

in vivo​ certification

The London-based firm then awards an in vivo​ certification recognising the product’s role in maintaining the microbiome.

The firm adds that the service is not exclusive to skincare, having carried out the tests for haircare products, oral products, intimate areas and physical surface management.

“The skin microbiome modulators market, for example, is growing at a lightning rate - expanding to nearly $3bn by 2030 at a CAGR of 15% (2020-2030),”​ highlights Sequential Skin’s CEO and cofounder, Dr Oliver Worsley.

"In today's world where the rising demand for transparency is becoming more and more important, and the effects ingredients have on the body are increasingly scrutinised, being able to test consumer products is critical.

"With the launch of Sequential Bio, companies now have a proven in-vivo capability, and we are looking forward to helping more clients to create microbiome friendly products while increasing consumer trust,"​ he adds.

‘Real world' conditions

Rob Calcraft, founder of Cultured Biomecare, and former founder of Ren skincare comments: "Utilising the Sequential Bio solution allowed us to conduct tests in 'real world' conditions on consumers.

“This novel in-vivo testing was pivotal for us as it validated our products as not just friendly, but also showed how beneficial it was for the skin microbiome.”

Meanwhile Dr. Lavienja Schreurs-Braam, founder of Vavin Skincare, a skincare firm based in the Netherlands adds: "Sequential Bio has helped us further our understanding of the intriguing world of the skin microbiome.

“By using their quality analysis we were able to confirm we are on the right track with developing skincare products for a healthy skin microbiome."

Related news

Show more

Related products

show more

Adopting B. longum BB536 in infant formula

Adopting B. longum BB536 in infant formula

Morinaga Milk Industry Co., Ltd. | 10-Jan-2023 | Technical / White Paper

Infant milk formula is one of the fastest-growing product categories in the baby food market, with China accounting for almost half of the global market...

Elasderma: Patented advance in molecule technology

Elasderma: Patented advance in molecule technology

Nutraceuticals Group | 05-Jan-2023 | Technical / White Paper

From Atlantic Cod, Elasderma is fully water soluble, additive free and a hydrolyzed form of Elastin that contains verifiable and quantitative levels of...

Related suppliers

Follow us


View more